Search

Your search keyword '"Hommel, Kristine"' showing total 39 results
Start Over Author "Hommel, Kristine" Publication Year Range Last 10 years
39 results on '"Hommel, Kristine"'

1. A comparison of the epidemiology of kidney replacement therapy between Europe and the United States: 2021 data of the ERA Registry and the USRDS

Author

Stel, Vianda S, primary, Boenink, Rianne, additional, Astley, Megan E, additional, Boerstra, Brittany A, additional, Radunovic, Danilo, additional, Skrunes, Rannveig, additional, Ruiz San Millán, Juan C, additional, Slon Roblero, Maria F, additional, Bell, Samira, additional, Ucio Mingo, Pablo, additional, ten Dam, Marc A G J, additional, Ambühl, Patrice M, additional, Resic, Halima, additional, Rodríguez Arévalo, Olga Lucia, additional, Aresté-Fosalba, Nuria, additional, Tort i Bardolet, Jaume, additional, Lassalle, Mathilde, additional, Trujillo-Alemán, Sara, additional, Indridason, Olafur S, additional, Artamendi, Marta, additional, Finne, Patrik, additional, Rodríguez Camblor, Marta, additional, Nitsch, Dorothea, additional, Hommel, Kristine, additional, Moustakas, George, additional, Kerschbaum, Julia, additional, Lausevic, Mirjana, additional, Jager, Kitty J, additional, Ortiz, Alberto, additional, and Kramer, Anneke, additional

Published
2024
Full Text
View/download PDF

5. The ERA Registry Annual Report 2021: a summary

Author

Boerstra, Brittany A, primary, Boenink, Rianne, additional, Astley, Megan E, additional, Bonthuis, Marjolein, additional, Abd ElHafeez, Samar, additional, Arribas Monzón, Federico, additional, Åsberg, Anders, additional, Beckerman, Pazit, additional, Bell, Samira, additional, Cases Amenós, Aleix, additional, Castro de la Nuez, Pablo, additional, ten Dam, Marc A G J, additional, Debska-Slizien, Alicja, additional, Gjorgjievski, Nikola, additional, Giudotti, Rebecca, additional, Helve, Jaakko, additional, Hommel, Kristine, additional, Idrizi, Alma, additional, Indriðason, Ólafur S, additional, Jarraya, Faiçal, additional, Kerschbaum, Julia, additional, Komissarov, Kirill S, additional, Kozliuk, Nadiia, additional, Kravljaca, Milica, additional, Lassalle, Mathilde, additional, De Meester, Johan M, additional, Ots-Rosenberg, Mai, additional, Plummer, Zoe, additional, Radunovic, Danilo, additional, Razvazhaieva, Olena, additional, Resic, Halima, additional, Rodríguez Arévalo, Olga Lucía, additional, Santiuste de Pablos, Carmen, additional, Seyahi, Nurhan, additional, Slon-Roblero, María Fernanda, additional, Stendahl, Maria, additional, Tolaj-Avdiu, Miloreta, additional, Trujillo-Alemán, Sara, additional, Ziedina, Ieva, additional, Ziginskiene, Edita, additional, Ortiz, Alberto, additional, Jager, Kitty J, additional, Stel, Vianda S, additional, and Kramer, Anneke, additional

Published
2023
Full Text
View/download PDF

6. Supplemented ERA-EDTA Registry data evaluated the frequency of dialysis, kidney transplantation, and comprehensive conservative management for patients with kidney failure in Europe

Author

Stel, Vianda S., de Jong, Rianne W., Kramer, Anneke, Andrusev, Anton M., Baltar, José M., Barbullushi, Myftar, Bell, Samira, Castro de la Nuez, Pablo, Cernevskis, Harijs, Couchoud, Cécile, De Meester, Johan, Eriksen, Bjørn O., Gârneaţă, Liliana, Golan, Eliezer, Helve, Jaakko, Hemmelder, Marc H., Hommel, Kristine, Ioannou, Kyriakos, Jarraya, Faiçal, Kantaria, Nino, Kerschbaum, Julia, Komissarov, Kirill S., Magaz, Ángela, Mercadal, Lucile, Ots-Rosenberg, Mai, Pálsson, Runólfur, Rahmel, Axel, Rydell, Helena, Savino, Manuela, Seyahi, Nurhan, Slon Roblero, Maria F., Stojceva-Taneva, Olivera, van der Tol, Arjan, Vazelov, Evgueniy S., Ziginskiene, Edita, Zurriaga, Óscar, Vanholder, Raymond C., Massy, Ziad A., and Jager, Kitty J.

Published
2021
Full Text
View/download PDF

8. The ERA Registry Annual Report 2021: a summary.

Author

Boerstra, Brittany A, Boenink, Rianne, Astley, Megan E, Bonthuis, Marjolein, ElHafeez, Samar Abd, Monzón, Federico Arribas, Åsberg, Anders, Beckerman, Pazit, Bell, Samira, Amenós, Aleix Cases, Nuez, Pablo Castro de la, Dam, Marc A G J ten, Debska-Slizien, Alicja, Gjorgjievski, Nikola, Giudotti, Rebecca, Helve, Jaakko, Hommel, Kristine, Idrizi, Alma, Indriðason, Ólafur S, and Jarraya, Faiçal

Subjects
CORPORATION reports, RENAL replacement therapy, CHRONIC kidney failure, KIDNEY transplantation, PERITONEAL dialysis, IGA glomerulonephritis
Abstract

Background The European Renal Association (ERA) Registry collects data on kidney replacement therapy (KRT) in patients with end-stage kidney disease (ESKD). This paper is a summary of the ERA Registry Annual Report 2021, including a comparison across treatment modalities. Methods Data was collected from 54 national and regional registries from 36 countries, of which 35 registries from 18 countries contributed individual patient data and 19 registries from 19 countries contributed aggregated data. Using this data, incidence and prevalence of KRT, kidney transplantation rates, survival probabilities and expected remaining lifetimes were calculated. Result In 2021, 533.2 million people in the general population were covered by the ERA Registry. The incidence of KRT was 145 per million population (pmp). In incident patients, 55% were 65 years or older, 64% were male, and the most common primary renal disease (PRD) was diabetes (22%). The prevalence of KRT was 1040 pmp. In prevalent patients, 47% were 65 years or older, 62% were male, and the most common PRDs were diabetes and glomerulonephritis/sclerosis (both 16%). On 31 December 2021, 56% of patients received haemodialysis, 5% received peritoneal dialysis, and 39% were living with a functioning graft. The kidney transplantation rate in 2021 was 37 pmp, a majority coming from deceased donors (66%). For patients initiating KRT between 2012–2016, 5-year survival probability was 52%. Compared to the general population, life expectancy was 65% and 68% shorter for males and females receiving dialysis, and 40% and 43% shorter for males and females living with a functioning graft. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Disparities in treatment and outcome of kidney replacement therapy in children with comorbidities: an ESPN/ERA Registry study

Author

Schild, Raphael, primary, Dupont, Simeon, additional, Harambat, Jérôme, additional, Vidal, Enrico, additional, Balat, Ayşe, additional, Bereczki, Csaba, additional, Bieniaś, Beata, additional, Brandström, Per, additional, Broux, Francoise, additional, Consolo, Silvia, additional, Gojkovic, Ivana, additional, Groothoff, Jaap W, additional, Hommel, Kristine, additional, Hubmann, Holger, additional, Braddon, Fiona E M, additional, Pankratenko, Tatiana E, additional, Papachristou, Fotios, additional, Plumb, Lucy A, additional, Podracka, Ludmila, additional, Prokurat, Sylwester, additional, Bjerre, Anna, additional, Cordinhã, Carolina, additional, Tainio, Juuso, additional, Shkurti, Enkelejda, additional, Spartà, Giuseppina, additional, Vondrak, Karel, additional, Jager, Kitty J, additional, Oh, Jun, additional, and Bonthuis, Marjolein, additional

Published
2023
Full Text
View/download PDF

13. Trends in kidney transplantation rate across Europe: study from the ERA Registry

Author

Boenink, Rianne, primary, Kramer, Anneke, additional, Tuinhout, Rosalie E, additional, Savoye, Emilie, additional, Åsberg, Anders, additional, Idrizi, Alma, additional, Kerschbaum, Julia, additional, Ziedina, Ieva, additional, Ziginskiene, Edita, additional, Farrugia, Emanuel, additional, Garneata, Liliana, additional, Zakharova, Elena V, additional, Bell, Samira, additional, Arnol, Miha, additional, Segelmark, Mårten, additional, Ioannou, Kyriakos, additional, Hommel, Kristine, additional, Rosenberg-Ots, Mai, additional, Vazelov, Evgueniy, additional, Helve, Jaakko, additional, Mihály, Sándor, additional, Pálsson, Runólfur, additional, Nordio, Maurizio, additional, Gjorgjievski, Nikola, additional, de Vries, Aiko P J, additional, Seyahi, Nurhan, additional, Magadi, Winnie A, additional, Resić, Halima, additional, Kalachyk, Aleh, additional, Rahmel, Axel O, additional, Galvão, Ana A, additional, Naumovic, Radomir, additional, Lundgren, Torbjörn, additional, Arici, Mustafa, additional, de Meester, Johan M, additional, Ortiz, Alberto, additional, Jager, Kitty J, additional, and Stel, Vianda S, additional

Published
2023
Full Text
View/download PDF

14. Trends in Mortality Due to Myocardial Infarction, Stroke, and Pulmonary Embolism in Patients Receiving Dialysis

Author

Ocak, Gurbey, primary, Boenink, Rianne, additional, Noordzij, Marlies, additional, Bos, Willem Jan W., additional, Vikse, Bjorn E., additional, Cases, Aleix, additional, Kerschbaum, Julia, additional, Helve, Jaakko, additional, Nordio, Maurizio, additional, Arici, Mustafa, additional, Mercadal, Lucile, additional, Wanner, Christoph, additional, Palsson, Runolfur, additional, Hommel, Kristine, additional, De Meester, Johan, additional, Kostopoulou, Myrto, additional, Santamaria, Rafael, additional, Rodrigo, Emilio, additional, Rydell, Helena, additional, Bell, Samira, additional, Massy, Ziad A., additional, Jager, Kitty J., additional, and Kramer, Anneke, additional

Published
2022
Full Text
View/download PDF

15. The ERA Registry Annual Report 2019: summary and age comparisons

Author

Boenink, Rianne, Astley, Megan E., Huijben, Jilske A., Stel, Vianda S., Kerschbaum, Julia, Ots-Rosenberg, Mai, Åsberg, Anders A., Lopot, Frantisek, Golan, Eliezer, Castro de la Nuez, Pablo, Rodríguez Camblor, Marta, Trujillo-Alemán, Sara, Ruiz San Millan, Juan Carlos, Ucio Mingo, Pablo, Díaz Gómez, Juan Manuel, Bouzas-Caamaño, M. Encarnación, Artamendi, Marta, Aparicio Madre, Manuel I, Santiuste de Pablos, Carmen, Slon Roblero, María Fernanda, Zurriaga, Oscar, Stendahl, Maria E., Bell, Samira, Idrizi, Alma, Ioannou, Kyriakos, Debska-Slizien, Alicja, Galvão, Ana A., De Meester, Johan, Resić, Halima, Hommel, Kristine, Radunovic, Danilo, Pálsson, Runolfur, Lassalle, Mathilde, Finne, Patrik, Garcia Bazaga, María De los Ángeles, Gjorgjievski, Nikola, Seyahi, Nurhan, Bonthuis, Marjolein, Ortiz, Alberto, Jager, Kitty J., Kramer, Anneke, Universitat Autònoma de Barcelona, Department of Medicine, Clinicum, Nefrologian yksikkö, Helsinki University Hospital Area, Graduate School, Medical Informatics, APH - Aging & Later Life, APH - Quality of Care, APH - Methodology, APH - Health Behaviors & Chronic Diseases, APH - Global Health, ACS - Pulmonary hypertension & thrombosis, and UAM. Departamento de Medicina

Subjects
Transplantation, patient survival, Medicina, Nephrology, 3121 General medicine, internal medicine and other clinical medicine, graft survival, dialysis, kidney transplantation, epidemiology, ESRD, 3126 Surgery, anesthesiology, intensive care, radiology
Abstract

Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, y los autores pertenecientes a la UAM, Data on renal replacement therapy (RRT) for end-stage renal disease were collected by the European Renal Association (ERA) Registry via national and regional renal registries in Europe and countries bordering the Mediterranean Sea. This article provides a summary of the 2019 ERA Registry Annual Report, including data from 34 countries and additional age comparisons. Methods: Individual patient data for 2019 were provided by 35 registries and aggregated data by 17 registries. Using these data, the incidence and prevalence of RRT, the kidney transplantation activity and the survival probabilities were calculated. In 2019, a general population of 680.8 million people was covered by the ERA Registry. Overall, the incidence of RRT was 132 per million population (p.m.p.). Of these patients, 62% were men, 54% were ≥65 years of age and 21% had diabetes mellitus as primary renal disease (PRD), and 84% had haemodialysis (HD), 11% had peritoneal dialysis (PD) and 5% had pre-emptive kidney transplantation as an initial treatment modality. The overall prevalence of RRT on 31 December 2019 was 893 p.m.p., with 58% of patients on HD, 5% on PD and 37% living with a kidney transplant. The overall kidney transplant rate was 35 p.m.p. and 29% of the kidney grafts were from a living donor. The unadjusted 5-year survival probability was 42.3% for patients commencing dialysis, 86.6% for recipients of deceased donor grafts and 94.4% for recipients of living donor grafts in the period 2010-14. When comparing age categories, there were substantial differences in the distribution of PRD, treatment modality and kidney donor type, and in the survival probabilities, The ERA Registry is funded by the ERA. This article was written by R. Boenink et al. on behalf of the ERA Registry, which is an official body of the ERA. In addition, S.B. reports personal fees from AstraZeneca, outside the submitted work; A.D.-S. reports personal fees from Astellas and Fresenius, outside the submitted work; F.L. reports personal fees from MeditesPharma, outside the submitted work; R.P. reports grants from The Iceland Centre for Research, Landspitali University Hospital Research Fund and University of Iceland Research Fund, outside the submitted work; P.F. reports grants from Finska läkaresällskapet and Liv och Hälsa, outside the submitted work; M.F.S.R. reports personal fees from Baxter and Fresenius, outside the submitted work; A.O. reports grants from Sanofi, and personal fees from Astellas, AstraZeneca, Amicus, Bayes, Fresenius Medical Care and Idorsia, outside the submitted work; and K.J.J. reports grants from ERA, during the conduct of the study

Published
2022

16. The ERA Registry Annual Report 2019: summary and age comparisons

Author

Boenink, Rianne, primary, Astley, Megan E, additional, Huijben, Jilske A, additional, Stel, Vianda S, additional, Kerschbaum, Julia, additional, Ots-Rosenberg, Mai, additional, Åsberg, Anders A, additional, Lopot, Frantisek, additional, Golan, Eliezer, additional, Castro de la Nuez, Pablo, additional, Rodríguez Camblor, Marta, additional, Trujillo-Alemán, Sara, additional, Ruiz San Millan, Juan Carlos, additional, Ucio Mingo, Pablo, additional, Díaz, Juan Manuel, additional, Bouzas-Caamaño, M Encarnación, additional, Artamendi, Marta, additional, Aparicio Madre, Manuel I, additional, Santiuste de Pablos, Carmen, additional, Slon Roblero, María Fernanda, additional, Zurriaga, Oscar, additional, Stendahl, Maria E, additional, Bell, Samira, additional, Idrizi, Alma, additional, Ioannou, Kyriakos, additional, Debska-Slizien, Alicja, additional, Galvão, Ana A, additional, De Meester, Johan M, additional, Resić, Halima, additional, Hommel, Kristine, additional, Radunovic, Danilo, additional, Pálsson, Runolfur, additional, Lassalle, Mathilde, additional, Finne, Patrik, additional, De los Ángeles-Garcia Bazaga, María, additional, Gjorgjievski, Nikola, additional, Seyahi, Nurhan, additional, Bonthuis, Marjolein, additional, Ortiz, Alberto, additional, Jager, Kitty J, additional, and Kramer, Anneke, additional

Published
2021
Full Text
View/download PDF

17. Incidence of Kidney Replacement Therapy and Subsequent Outcomes Among Patients With Systemic Lupus Erythematosus: Findings From the ERA Registry

Author

Derner, Ondrej, primary, Kramer, Anneke, additional, Hruskova, Zdenka, additional, Arici, Mustafa, additional, Collart, Frederic, additional, Finne, Patrik, additional, Fuentes Sánchez, Laura, additional, Harambat, Jérôme, additional, Hemmelder, Marc H., additional, Hommel, Kristine, additional, Kerschbaum, Julia, additional, De Meester, Johan, additional, Palsson, Runolfur, additional, Segelmark, Mårten, additional, Skrunes, Rannveig, additional, Traynor, Jamie P., additional, Zurriaga, Oscar, additional, Massy, Ziad A., additional, Jager, Kitty J., additional, Stel, Vianda S., additional, and Tesar, Vladimir, additional

Published
2021
Full Text
View/download PDF

19. The ERA-EDTA Registry Annual Report 2018: a summary

Author

Kramer, Anneke, primary, Boenink, Rianne, additional, Stel, Vianda S, additional, Santiuste de Pablos, Carmen, additional, Tomović, Filip, additional, Golan, Eliezer, additional, Kerschbaum, Julia, additional, Seyahi, Nurhan, additional, Ioanou, Kyriakos, additional, Beltrán, Palma, additional, Zurriaga, Oscar, additional, Magaz, Ángela, additional, Slon Roblero, María F, additional, Gjorgjievski, Nikola, additional, Garneata, Liliana, additional, Arribas, Federico, additional, Galvão, Ana A, additional, Bell, Samira, additional, Ots-Rosenberg, Mai, additional, Muñoz-Terol, José M, additional, Winzeler, Rebecca, additional, Hommel, Kristine, additional, Åsberg, Anders, additional, Spustova, Viera, additional, Palencia García, María Ángeles, additional, Vazelov, Evgueniy, additional, Finne, Patrik, additional, ten Dam, Marc A G J, additional, Lopot, František, additional, Trujillo-Alemán, Sara, additional, Lassalle, Mathilde, additional, Kolesnyk, Mykola O, additional, Santhakumaran, Shalini, additional, Idrizi, Alma, additional, Andrusev, Anton, additional, Comas Farnés, Jordi, additional, Komissarov, Kirill, additional, Resić, Halima, additional, Palsson, Runolfur, additional, Kuzema, Viktorija, additional, Garcia Bazaga, Maria Angeles, additional, Ziginskiene, Edita, additional, Stendahl, Maria, additional, Bonthuis, Marjolein, additional, Massy, Ziad A, additional, and Jager, Kitty J, additional

Published
2020
Full Text
View/download PDF

20. The ERA-EDTA Registry Annual Report 2017

Author

Kramer, Anneke, Boenink, Rianne, Noordzij, Marlies, Bosdriesz, Jizzo R., Stel, Vianda S., Beltrán, Palma, Ruiz, Juan C., Seyahi, Nurhan, Comas Farnés, Jordi, Stendahl, Maria, Garneata, Liliana, Winzeler, Rebecca, Golan, Eliezer, Lopot, František, Korejwo, Grzegorz, Bonthuis, Marjolein, Lassalle, Mathilde, Slon Roblero, María F., Kuzema, Viktorija, Hommel, Kristine, Stojceva-Taneva, Olivera, Åsberg, Anders, Kramar, Reinhard, Hemmelder, Marc H., de Meester, Johan, Vazelov, Evgueniy, Andrusev, Anton M., Castro de la Nuez, Pablo, Helve, Jaakko, Komissarov, Kirill, Casula, Anna, Magaz, Ángela, Santiuste de Pablos, Carmen, Bubic, Ivan, Traynor, Jamie P., Ioannou, Kyriakos, Idrizi, Alma, Palsson, Runolfur, des Grottes, Jean-Marin, Spustova, Viera, Tolaj-Avdiu, Miloreta, Nordio, Maurizio, Ziginskiene, Edita, Massy, Ziad A., Jager, Kitty J., APH - Quality of Care, APH - Aging & Later Life, ACS - Pulmonary hypertension & thrombosis, Medical Informatics, Graduate School, Infectious diseases, APH - Methodology, APH - Health Behaviors & Chronic Diseases, Amsterdam Gastroenterology Endocrinology Metabolism, and APH - Global Health

Published
2020

21. Correction to: Is metformin associated with acute kidney injury? A case–control study of patients with type 2 diabetes admitted with acute infection

Author

Schytz, Philip Andreas, primary, Nissen, Anders Bonde, additional, Hommel, Kristine, additional, Schou, Morten, additional, Nelveg-Kristensen, Karl Emil, additional, Torp-Pedersen, Christian, additional, Gislason, Gunnar H., additional, Gerds, Thomas A., additional, and Carlson, Nicholas, additional

Published
2020
Full Text
View/download PDF

23. Incidence of Kidney Replacement Therapy and Subsequent Outcomes Among Patients With Systemic Lupus Erythematosus: Findings From the ERA Registry

Author

Derner, Ondrej, Kramer, Anneke, Hruskova, Zdenka, Arici, Mustafa, Collart, Frederic, Finne, Patrik, Fuentes Sánchez, Laura, Harambat, Jérôme, Hemmelder, Marc H., Hommel, Kristine, Kerschbaum, Julia, De Meester, Johan, Palsson, Runolfur, Segelmark, Mårten, Skrunes, Rannveig, Traynor, Jamie P., Zurriaga, Oscar, Massy, Ziad A., Jager, Kitty J., Stel, Vianda S., and Tesar, Vladimir

Abstract

There is a dearth of data characterizing patients receiving kidney replacement therapy (KRT) for kidney failure due to systemic lupus erythematosus (SLE) and their clinical outcomes. The aim of this study was to describe trends in incidence and prevalence of KRT among these patients as well as to compare their outcomes versus those of patients treated with KRT for diseases other than SLE.

Published
2022
Full Text
View/download PDF

29. Metformin-associated risk of acute dialysis in patients with type 2 diabetes:a nationwide cohort study

Author

Carlson, Nicholas, Hommel, Kristine, Olesen, Jonas Bjerring, Gerds, Thomas Alexander, Soja, Anne-Merete, Vilsbøll, Tina, Kamper, Anne-Lise, Torp-Pedersen, Christian, and Gislason, Gunnar

Abstract

Recent guidelines governing anti-diabetic medications increasingly advocate metformin as first-line therapy in all patients with type 2 diabetes. However, metformin could be associated with increased risk of acute kidney injury (AKI), acute dialysis, and lactate acidosis in marginal patients. In a retrospective nationwide cohort study, a total of 168,443 drug-naïve patients with type 2 diabetes ≥50 years initiating treatment with either metformin or sulphonyl in Denmark between 2000 and 2012 were included (70.7% initiated treatment with metformin), and one-year risk of acute dialysis was calculated based on g-standardization of cause-specific Cox regression models for acute dialysis, end-stage renal disease, and death. One-year risks of acute dialysis were 92.4 per 100,000 (95% CI 67.1 - 121.3) and 142.7 per 100,000 (95% CI 118.3 - 168.0), for sulphonylurea and metformin, respectively. The metformin-associated one-year risk of acute dialysis was increased by 50.3 per 100,000 (95% CI 7.9 - 88.6), corresponding to a risk ratio of 1.53 (95% CI 1.06 - 2.23), and a number needed to harm of 1988; thus providing evidence of potential concerns pertaining to the increasing use of metformin.

Published
2016

37. Differences in survival on chronic dialysis treatment between ethnic groups in Denmark: a population-wide, national cohort study.

Author

van den Beukel, Tessa O., Hommel, Kristine, Kamper, Anne-Lise, Heaf, James G., Siegert, Carl E. H., Honig, Adriaan, Jager, Kitty J., Dekker, Friedo W., and Norredam, Marie

Subjects
*HEMODIALYSIS, *ETHNIC groups, *DISEASES, *MORTALITY, *DISEASE incidence, *MEDICAL research
Abstract

Background. In Western countries, black and Asian dialysis patients experience better survival compared with white patients. The aim of this study is to compare the survival of native Danish dialysis patients with that of dialysis patients originating from other countries and to explore the association between the duration of residence in Denmark before the start of dialysis and the mortality on dialysis. Methods. We performed a population-wide national cohort study of incident chronic dialysis patients in Denmark (≥18 years old) who started dialysis between 1995 and 2010. Results. In total, 8459 patients were native Danes, 344 originated from other Western countries, 79 from North Africa or West Asia, 173 from South or South-East Asia and 54 from sub-Saharan Africa. Native Danes were more likely to die on dialysis compared with the other groups (crude incidence rates for mortality: 234, 166, 96, 110 and 53 per 1000 personyears, respectively). Native Danes had greater hazard ratios (HRs) for mortality compared with the other groups {HRs for mortality adjusted for sociodemographic and clinical characteristics: 1.32 [95% confidence interval (CI) 1.14-1.54]; 2.22 [95% CI 1.51-3.23]; 1.79 [95% CI 1.41-2.27]; 2.00 [95% CI 1.10-3.57], respectively}. Compared with native Danes, adjusted HRs for mortality for Western immigrants living in Denmark for ὄ10 years, >10 to ὄ20 years and >20 yearswere 0.44 (95% CI 0.27-0.71), 0.56 (95% CI 0.39-0.82) and 0.86 (95% CI 0.70-1.04), respectively. For non-Western immigrants, these HRs were 0.42 (95% CI 0.27-0.67), 0.52 (95% CI 0.33-0.80) and 0.48 (95% CI 0.35-0.66), respectively. Conclusions. Incident chronic dialysis patients in Denmark originating from countries other than Denmark have a better survival compared with native Danes. ForWestern immigrants, this survival benefit declines among those who have lived in Denmark longer. For non-Western immigrants, the survival benefit largely remains over time. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

38. Changes in the epidemiology of kidney replacement therapy across Europe in 2020 - the first year of the COVID-19 pandemic: an ERA Registry study.

Author

Kramer A, Jager KJ, Chesnaye NC, Kerschbaum J, Hommel K, Farnés JC, Alemán ST, Santamaria R, Finne P, Hemmelder MH, Åsberg A, Nitsch D, Ambühl P, Sørensen SS, Sánchez-Alvarez JE, Segelmark M, Resic H, Ots-Rosenberg M, Radunovic D, Palsson R, de Pablos CS, Arévalo OLR, Legeai C, Lausevic M, Bakkaloglu SA, Ortiz A, and Stel VS

Abstract

Background: In 2020, the COVID-19 pandemic caused disruptions in kidney replacement therapy (KRT) services worldwide. The aim of this study was to assess the effect of the COVID-19 pandemic in 2020 on the incidence of KRT, kidney transplantation activity, mortality and prevalence of KRT across Europe., Methods: Patients receiving KRT were included from 17 countries providing data to the European Renal Association Registry. The epidemiology of KRT in 2020 was compared with average data from the period 2017-2019. Also changes occurring during the first and second wave of the pandemic were explored., Results: The incidence of KRT was 6.2% lower in 2020 compared with 2017-2019, with the lowest point (-22.7%) during the first wave in April. The decrease varied across countries, was smaller in males (-5.2%) than in females (-8.2%), and was moderate for peritoneal dialysis (-3.7%) and haemodialysis (-5.4%), but substantial for pre-emptive kidney transplantation (-23.6%). The kidney transplantation rate decreased by 22.5%, reaching a nadir of -80.1% during the first wave, and most for living donor kidney transplants (-30.5%). While in most countries the kidney transplantation rate decreased, in the Nordic/Baltic countries and Greece there was no clear decline. In dialysis patients, mortality increased by 11.4%, and was highest in those aged 65-74 years (16.1%), in those with diabetes as primary renal disease (15.1%), and in those on haemodialysis (12.4%). In transplant recipients, the mortality was 25.8% higher, but there were no subgroups that stood out. In contrast to the rising prevalence of KRT observed over the past decades across Europe, the prevalence at the end of 2020 (N=317787) resembled that of 2019 (N=317077)., Conclusion: The COVID-19 pandemic has had a substantial impact on the incidence of KRT, kidney transplant activity, mortality of KRT, and prevalence of KRT in Europe with variations across countries., (© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.)

Published
2024
Full Text
View/download PDF

39. Incidence and outcomes of kidney replacement therapy for end-stage kidney disease due to primary glomerular disease in Europe: findings from the ERA Registry.

Author

ElHafeez SA, Kramer A, Arici M, Arnol M, Åsberg A, Bell S, Belliere J, Corte CD, Fresnedo GF, Hemmelder M, Heylen L, Hommel K, Kerschbaum J, Naumović R, Nitsch D, Santamaria R, Finne P, Palsson R, Pippias M, Resic H, Rosenberg M, de Pablos CS, Segelmark M, Sørensen SS, Soler MJ, Vidal E, Jager KJ, Ortiz A, and Stel VS

Abstract

Background and Hypothesis: Primary glomerular disease (PGD) is a major cause of end-stage kidney disease (ESKD) leading to kidney replacement therapy (KRT). We aimed to describe incidence (trends) in individuals starting KRT for ESKD due to PGD and to examine their survival and causes of death., Methods: We used data from the European Renal Association (ERA) Registry on 69 854 patients who started KRT for ESKD due to PGD between 2000 and 2019. ERA primary renal disease codes were used to define six PGD subgroups. We examined age and sex standardized incidence, trend of the incidence, and survival., Results: The standardized incidence of KRT for ESKD due to PGD was 16.6 per million population (pmp), ranging from 8.6 pmp in Serbia to 20.0 pmp in France. IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) had the highest incidence of 4.6 pmp and 2.6 pmp, respectively. Histologically non-examined PGDs represented over 50% of cases in Serbia, Bosnia and Herzegovina, and Romania and were also common in Greece, Estonia, Belgium, and Sweden. The incidence declined from 18.6 pmp in 2000 to 14.5 pmp in 2013, after which it stabilized. All PGD subgroups had five-year survival probabilities above 50%, with crescentic glomerulonephritis having the highest risk of death (adjusted hazard ratio: 1.8 [95% confidence interval: 1.6-1.9]) compared with IgAN. Cardiovascular disease was the most common cause of death (33.9%)., Conclusion: The incidence of KRT for ESKD due to PGD showed large differences between countries and was highest and increasing for IgAN and FSGS. Lack of kidney biopsy facilities in some countries may have affected accurate assignment of the cause of ESKD. The recognition of the incidence and outcomes of KRT among different PGD subgroups may contribute to a more individualized patient care approach., (© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results